Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives
ConclusionsThe introduction of biosimilar bevacizumab-bvzr was estimated to provide substantial cost savings for US payers, which would allow additional patients access to bevacizumab treatment.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Colorectal Cancer | Economics | Health Management | Medicare | Study